Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.39 |
| ▸ | RXRA | P19793 | 3/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18157616 | 0.94 | NR1H2 (0.41) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157610 | 0.93 | NR1H2 (0.41) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157622 | 0.93 | NR1H2 (0.41) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157617 | 0.91 | PTGS2 (0.52) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18145465 | 0.91 | NR1H2 (0.51) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157570 | 0.90 | PTGS2 (0.44) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157618 | 0.90 | NR1H2 (0.40) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157653 | 0.90 | PTGS2 (0.53) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157496 | 0.90 | PTGS2 (0.45) | PTGS2NR1H2PTGS1NR1H3RXRA | |
| SCHEMBL18157603 | 0.89 | PTGS2 (0.47) | PTGS2NR1H2PTGS1NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304499-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | PTGS2 1661/4885NR1H2 1/4885PTGS1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.